Alkem Laboratories Limited has informed the Exchange regarding a press release dated Jun 02, 2026, titled "Alkem Laboratories Limited becomes first in India to launch semaglutide in single-shot pre-filled syringes at price starting INR350.".
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alkem Laboratories has announced the launch of semaglutide in single-shot pre-filled syringes, claiming to be the first company in India to offer this format. The product will be priced starting at INR 350 per unit. Semaglutide is a key drug used in the treatment of type-2 diabetes and weight management. This launch places Alkem ahead of competitors currently offering the molecule in oral tablet form. The move is expected to strengthen Alkem's presence in the fast-growing diabetes and obesity care segment.
Positive for the company — first-mover status and affordable pricing could boost revenue from the diabetes and obesity portfolio, though the contribution to overall financials will depend on uptake and competitive response.